- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Research From PBMI Reveals Overall PBM Satisfaction is at All-Time High
Results from the 2018 Pharmacy Benefit Manager (PBM) Customer Satisfaction Report have revealed that plan sponsors gave an overall PBM satisfaction score of 8.0, which is the highest score in 5 years.
Results from the 2018 Pharmacy Benefit Manager (PBM) Customer Satisfaction Report have revealed that plan sponsors gave an overall PBM satisfaction score of 8.0, which is the highest score in 5 years. The report, released by the Pharmacy Benefit Management Institute, includes metrics for non-specialty drug utilization and costs, place of service, and specialty drug utilization costs. Each area was scored on a scale of 1 to 10, with 10 representing the highest rate of satisfaction.
However, the report also highlghted several areas for improvement, such as custimzation and greater flexibility, improved accuracy, predictive modeling for plan design changes, and dashboards. Read more about the report.
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
What We’re Reading: New HPV Screenings; Lung Cancer Pills; Migraine Relief Device
November 9th 2023A study suggests that human papillomavirus (HPV) screenings should be updated due to effective HPV vaccines; a new study shows that osimertinib (Tagrisso, AstraZeneca) reduced both the 5-year risk of recurrent cancer and the risk of death in patients with stage 1B to 3A lung cancer; a new smartphone-controlled technology could help those who suffer from migraines.
Read More
